Newer molecules in the treatment of schizophrenia: A clinical update

Indian Journal of Pharmacology

Volumn 43, Issue 2, 2011, Pages 105-112

  Ghosh, Abhishek ^a   Chakraborty, Kaustav ^a   Mattoo, Surendra ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Drugs; molecules; neurotransmitters; novel; schizophrenia

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMISULPRIDE; ASENAPINE; BIFEPRUNOX; CELECOXIB; CERULETIDE; CHLORPROMAZINE; CLOZAPINE; CX 619; CX 717; CYCLOSERINE; DEXTRO SERINE; DOCOSAHEXAENOIC ACID; FARAMPATOR; GLYCINE; HALOPERIDOL; ICOSAPENTAENOIC ACID; ILOPERIDONE; ISPRONICLINE; LAMOTRIGINE; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PALIPERIDONE; PIMAVANSERIN; PLACEBO; RIMCAZOLE; RISPERIDONE; SARCOSINE; STEPHOLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADJUVANT THERAPY; AKATHISIA; CATALEPSY; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONVULSIVE THERAPY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; ERUCTATION; EXTRAPYRAMIDAL SYMPTOM; FASCICULATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; MOTOR NEURON DISEASE; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPHIL COUNT; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PERCEPTION DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); POSITIVE SYNDROME; PSYCHOSIS; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT; WEIGHT GAIN;

EID: 79957540263     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.77334     Document Type: Review

References (49)

1. th ed. Philadelphia, USA: Williams & Wilkins; 2009. p. 1433-50.
2. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation. Acta Psychiatr Scand 2009;438:7-14.
3. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63.
4. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-30. (Pubitemid 47347922)
5. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007;61:1356-70. (Pubitemid 47052363)
6. Heresco-levy U. Amino acid transmitter systems in schizophrenia and other psychotic disorders. Biol Psychiatry 2002;21:587-600.
7. Heresco-levy U, Javitt DC. Comparative effects of glycine and D cycloserine on persistent negative symptom in schizophrenia: A retrospective analysis. Schizophr Res 2004;66:89-96. (Pubitemid 38041106)
8. Javitt DC, Duncan L, Ball A, Sershen H. Inhibition of System mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action. Biol Psychiatry 2005;10:275-87.
9. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter 1 inhibitor N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55:452-6. (Pubitemid 38338531)
10. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, et al. A placeb-ocontrolled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21:484-7. (Pubitemid 32937430)
11. Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G, et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series. Schizophr Res 2002;57:221-6. (Pubitemid 35240024)
12. Org 24448 selected to test efficacy in treatment of cognitive dysfunction in schizophrenia, Organon [Online]. 2005 Jan 24; Available from: http://www.medicalnewstoday.com/articles/19183.php [last cited on 2010 Feb 23].
13. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson Ml. Interactions between monoamines, glutamate and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 2001;41:237-60. (Pubitemid 32385889)
14. Krystal JH, D'souza Dc, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacol 2003;169:215-33.
15. Tiihonen J, Hallikainen T, Ryynanen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, et al.. Lamotrigine in treatment-resistant schizophrenia: A randomized placebocontrolled crossover trial. Biol Psychiatry 2003;54:1241-8.
16. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, et al.. Placebocontrolled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004;56:441-6.
17. Tiihonen J, Hallikainen T, Ryynanen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, et al.. Lamotrigine in treatment-resistant schizophrenia: A randomized placebocontrolled crossover trial. Biol Psychiatry 2003;54:1241-8.
18. Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004;174:54-64. (Pubitemid 38925091)
19. Briggs CA, McKenna DG, Piattoni-Kaplan M. Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 1995;34:583-90.
20. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-30. (Pubitemid 47347922)
21. Dunbar G, Boeijinga PH, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K, et al.. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 2007;191:919-29.
22. Dean B, Bymaster FP, Scarr E. Muscarinic receptors in schizophrenia. Curr Mol Med 2003;3:419-26. (Pubitemid 36975101)
23. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997;36:609-20. (Pubitemid 27272106)
24. ACADIA Pharmaceuticals. Pimavanserin. Available from: http://www.acadiapharm.com/pipeline/pimavanserin.htm [last cited in 2007].
25. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004;174:17-24. (Pubitemid 38925086)
26. Wijtmans M, Leurs R, Esch I. Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Investig Drugs 2007;16:967-85. (Pubitemid 47074155)
27. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, et al.. GSK189254 - a novel H3 receptor antagonist that binds to histamine H 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321:1032-45. (Pubitemid 46762709)
28. Yves C, Danielle DP, Philippe B, Christiane G, Nathalie A, Richard A. SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1 Receptor Agonist. I: Neurochemical and Electrophysiological Profile. Neuropsychopharmacology 2003;28:2064-76.
29. Depoortere R, Bardin L, Auclair A, Bruins L, Kleven A, Newman T. F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: II. Profile in models predictive of efficacy against positive, negative symptoms and cognitive deficits of schizophrenia. Eur Neuropsychopharmacology 2008;16:434-4.
30. Sridhar S, Karen B, Greg ER, John O, Jose NN, Glen BB, et al. The antipsychotic potential of l-stepholidine - a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology 2008;199:275-89.
31. Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilström B, et al. Asenapine, a novel psychopharmacologic agent: Preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-29. (Pubitemid 351200428)
32. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of Asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-500. (Pubitemid 350073395)
33. Potkin SG, Kane JM, Emsley R, Naber D, Panagides J. Asenapine in Schizophrenia: An Overview of Clinical Trials in the Olympia Program. Schizophr Res 2008;102:258.
34. Emsley R, Schoemaker JH, Vrijland P. Long-Term Safety of Asenapine versus Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. US Psychiatric and Mental Health Congress. San Diego, Oct 30 - Nov 2, 2008.
35. Corbett R, Griffiths L, Shipley JE, Shukla U, Strupczewski JT, Szczepanik AM, et al. Iloperidone: Preclinical profile and early clinical evaluation. CNS Drug Rev 1997;3:120-47. (Pubitemid 27509410)
36. ACADIA Pharmaceuticals. ACADIA Pharmaceuticals announces results from ACP-104 IIb schizophrenia trial [online]. Available from: http://news.acadia- pharm.com [last cited in 2010].
37. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: Results from a randomized, double-blind, placebo-controlled, multicenter, dose finding study. Psychopharmacology (Berl) 2008;200:317-31.
38. Bourin M, Debelle M, Heisterberg J. Bifeprunox is safe and effective in preventing deterioration in patients with stable schizophrenia: Results from a 6-month, placebo-controlled study [abstract]. Schizophr Bull 2007;33:422.
39. Puri BK, Richardson AJ, Horrobin DF, Easton T, Saeed N, Oatridge A, et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalization of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract 2000;54:57-63. (Pubitemid 30088763)
40. Peet M, Horrobin DF; EE Multi Centre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36:7-18. (Pubitemid 34037843)
41. Haller J, Szirmai M, Varga B, Ledent C, Freund TF. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 2005;16:415-22. (Pubitemid 41404813)
42. Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrié P, et al. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea pig. Neuropeptides 1998;32:481-6.
43. Evangelista S. Talnetant, GlaxoSmithKline. Curr Opin Investig Drugs 2005;6:717-21.
44. Feifel D, Tammi R, Robeck S. Antipsychotic Potential of CCK-Based Treatments: An assessment using the pre-pulse inhibition model of psychosis. Neuropsychopharmacology 1999;20:141-9. (Pubitemid 29010373)
45. Shibuya H, Mori H, Toru M. Sigma receptors in schizophrenic cerebral cortices Neurochem Res 1992;17:983-90.
46. Mullar N, Strassing M, Scwartz M, Utmschneider M, Reidel M. COX II inhibitors as adjunctive therapy in schizophrenia Expert Opin Investig Drugs 2004;13:1033-44.
47. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001;25:402-9. (Pubitemid 32777790)
48. Akbarian S. Restoring GABAergic Signaling and Neuronal Synchrony in Schizophrenia. Am J Psychiatry 2008;165:1507-9.
49. Anderson MB, Fuxe K, Werge T, Gerlach J. The Adenosine receptor agonist CGS 21680 exhibits antipsychotics like activity in Cabus paella monkeys. Behav Pharmacol 2002;3:639-44. (Pubitemid 36132594)